Loading data for RNA — first visit, this takes a few seconds.
Atrium Therapeutics Inc. (RNA)
NasdaqGS: RNA
· Real-Time Price · USD
12.84
-0.12 (-0.93%)
At close: Aug 18, 2026, 3:59 PM
Atrium Therapeutics Inc. (RNA) Stock Price, Analysis & Data
-0.93% (1D)
| Bid | 9.26 |
| Market Cap | 228.53M |
| Revenue (ttm) | 35.84M |
| Net Income (ttm) | -65.99M |
| Beta | n/a |
| EPS (ttm) | -5.44 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.66 |
| P/B (ttm) | 0.98 |
| P/S (ttm) | 6.38 |
| Earnings Date | May 11, 2026 |
| Ask | 16.35 |
| Volume | 107,895 |
| Avg. Volume (20D) | 191,122 |
| Open | 12.91 |
| Previous Close | 12.96 |
| Day's Range | 12.76 - 12.96 |
| 52-Week Range | 11.13 - 16.77 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RNA
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipe...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 27, 2026
Employees n/a
Stock Exchange NasdaqGS
Ticker Symbol RNA
Website https://atriumtherapeutics.com
Financial Performance
In 2025, Atrium Therapeutics's revenue was 18.62M, an increase of 70.85% compared to the previous year's 10.9M. Earnings were -76.68M, an increase of 205.25%.
Financial StatementsEarnings Surprise
Atrium Therapeutics has released their quarterly earnings on Aug 13, 2026:
Atrium Therapeutics Inc. is scheduled to release its earnings on May 11, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2